Table 1. Clinicopathologic features of 14 cases with primary ovarian endometrioid stromal sarcomas.

Case	Age,y	Laterality	Size	Grade	Stage	Treatment	RFS(mo)	Location ofrecurrence	Status(mo)	Status uterus
1	40	Right	8	LG	III	TH+BSO, L, A, tumor debulking, RT, HT	–	–	NED(55)	Serosa involved
2	54	Left	5	LG	III	BSO, tumor debulking, RT, CT	252	Retroperitoneum	AWD(311)	Myoma
3	40	Left	8	LG	III	TH+BSO, L, A, tumor debulking, CT, HT	–	–	NED(76)	Negative
4	43	Right	18	LG	I	TH+BSO	–	–	NED(140)	Negative
5	34	Bilateral	4, 8	LG	III	TH+BSO, L, tumor debulking, CT	–	–	NED(48)	Negative
6	61	Right	14	LG	I	BSO, A, CT	–	–	NED(54)	Myoma
7	60	Left	5	LG	I	TH+BSO, A, HT	–	–	NED(121)	Negative
8	43	Right	Unk	LG	I	TH+RSO	30	Left ovary, Rectum,	NED(64)	Negative
9	50	Bilateral	Unk	LG	III	BSO, tumor debulking, CT	8	Rectum	NED(66)	Negative
10	59	Left	Unk	HG	I	TH+BSO, L, A, CT	22	Pelvis, rectum	AWD(72)	Negative
11	53	Right	15	HG	III	BSO, tumor debulking, CT	–	–	NED(8)	Myoma
12	61	Bilateral	Unk	HG	III	TH+BSO, L, A, tumor debulking, CT	24	Pelvis, colon	DOD(112)	Negative
13	34	Right	Unk	HG	I	TH+RSO, A, CT	12	Pelvis, sigmoid colon, rectum	DOD(18)	Negative
14	55	Right	8	HG	III	TH+BSO, L, A, tumor debulking, CT	8	Pelvis, colon, liver	AWD(17)	Serosa involved

LG, low-grade; HG, high-grade; TH, total hysterectomy; BSO, bilateral salpingo-oophorectomy; RSO, right salpingo-oophorectomy; L, lymph node dissection; A, appendicectomy; RT, radiotherapy; CT, chemotherapy; HT, hormonal therapy; RFS, recurrence-free survival; NED, no evidence of disease; AWD, Alive with disease; DOD, dead of disease; Unk, unknown.